Effect of Vortioxetine on Cognitive Symptoms in Patients With Schizophrenia
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Research goals:
1. Examination of the relationship between the use of vortioxetine and cognitive efficacy
in patients with schizophrenia.
2. Examination of the association between the use of vortioxetine and the presence
depressive symptoms, physical and social anhedonia in patients with the disease from
schizophrenia.
3. Examining the association between vortioxetine use and quality of life
(functional recovery) in patients with schizophrenia
Expected results (hypotheses)
1. Patients with schizophrenia treated with additional therapy vortioxetine will show
better cognitive achievement in memory (short-term and long-term), attention, logical
reasoning and reasoning, speed of information processing, processing of visual and sound
information, language and speech in relation to patients without additional
intervention.
2. Patients with schizophrenia treated with additional therapy vortioxetine will have a
less pronounced presence of depressive symptoms, physical and social anhedonia in
relation to untreated patients with additional vortioxetine therapy.
3. Patients with schizophrenia who were treated with additional therapy vortioxetine will
have a better quality of life, ie. better functional recovery